Immunovant (IMVT) – Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Immunovant (NASDAQ: IMVT) in the last few weeks:

• 10/2/2026 – Immunovant had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/24/2026 – Immunovant had its “buy” rating reaffirmed by HC Wainwright.
• 9/24/2026 – Immunovant had its “positive” rating reaffirmed by Citigroup Inc..
• 9/23/2026 – Immunovant had its “buy” rating reaffirmed by UBS Group AG.
• 8/25/2026 – Immunovant had its “overweight” rating reaffirmed by Cantor Fitzgerald.

Insider Buying and Selling

In related news, CEO Eric Venker sold 3,506 shares of the company’s stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $34.11, for a total transaction of $119,589.66. Following the sale, the chief executive officer owned 257,075 shares in the company, valued at approximately $8,768,828.25. This represents a 1.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Christopher Van Tuyl sold 2,846 shares of the stock in a transaction that occurred on Wednesday, September 23rd. The shares were sold at an average price of $36.36, for a total value of $103,480.56. Following the transaction, the insider directly owned 176,545 shares of the company’s stock, valued at $6,419,176.20. This trade represents a 1.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 15,229 shares of company stock worth $524,482 over the last three months. Company insiders own 1.90% of the company’s stock.

Immunovant, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases. The company’s approach centers on targeting the neonatal Fc receptor (FcRn), a protein involved in the recycling of immunoglobulin G antibodies that can contribute to autoimmune activity.

Immunovant’s lead product candidate is batoclimab (IMVT-1401), a fully human monoclonal antibody designed to reduce circulating disease-causing antibodies. The company has evaluated batoclimab in several autoimmune conditions, including generalized myasthenia gravis and Graves’ disease, and has also pursued development in other antibody-mediated disorders.